Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Omer Zaidi"'
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Immunoglobulin type A (IgA) nephropathy is the most common primary glomerulonephritis (GN) worldwide with higher rates in East and Pacific Asia compared to North America and Europe. Despite high reported prevalence of IgAN in thes
Externí odkaz:
https://doaj.org/article/ee8e091765684ad7ba82c24795a29525
Autor:
Pei-Jen Lou, Wanatpreeya Phongsamart, Isaya Sukarom, Ying-Hui Wu, Omer Zaidi, Frieda Du, Alyssa Simon, Mark Bernauer
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Compared with Europe and America, adoption of human papillomavirus (HPV) vaccination into national immunization programs across the Asia-Pacific (AP) region has remained low. Moreover, HPV burden in this region has not been reviewed comprehensively.
Externí odkaz:
https://doaj.org/article/8b647d29c6304e5e9022ad88ffdd9664
Autor:
Wanatpreeya Phongsamart, Pei-Jen Lou, Isaya Sukarom, Ying-Hui Wu, Omer Zaidi, Frieda Du, Alyssa Simon, Mark Bernauer
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
There is limited literature on current human papillomavirus (HPV) vaccination in the Asia-Pacific region. This integrative literature review was conducted to describe HPV vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the
Externí odkaz:
https://doaj.org/article/cbc714e9370d49f19a4110820bb07d97
Publikováno v:
Heart Failure Reviews. 27:741-753
In clinical practice, many patients with heart failure with reduced ejection fraction (HFrEF) are either not prescribed guideline-directed medical therapies for which they are eligible or are prescribed therapies at sub-target doses. The objective of
Publikováno v:
Journal of Medical Economics. 24:665-674
NYVEPRIA, a pegfilgrastim (a long-acting granulocyte colony-stimulating factor [G-CSF]) biosimilar, was recently recommended for marketing authorization in Europe for decreasing the incidence of febrile neutropenia (FN) in patients with non-myeloid m
Publikováno v:
Future oncology (London, England).
Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL) in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably attributable to underdosed FIL in practice. We used real-world data to
Autor:
Terapong Tantawichien, Li Yang Hsu, Omer Zaidi, Mark Bernauer, Frieda Du, Eriko Yamada, Jin Oh Kim, Isaya Sukarom
Publikováno v:
Expert review of vaccines. 21(2)
Pneumococcal diseases are common and cause significant morbidity and mortality, with higher rates especially in developing areas including many in the Asia-Pacific (AP) region. However, current strategies to prevent pneumococcal disease in adults are
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S391
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S174
Autor:
Stephen J, Greene, Xi, Tan, Yu-Chen, Yeh, Mark, Bernauer, Omer, Zaidi, Mei, Yang, Javed, Butler
Publikováno v:
Heart failure reviews. 27(3)
In clinical practice, many patients with heart failure with reduced ejection fraction (HFrEF) are either not prescribed guideline-directed medical therapies for which they are eligible or are prescribed therapies at sub-target doses. The objective of